Last reviewed · How we verify
Low dose nadroparin
Low dose nadroparin is a Low-molecular-weight heparin (LMWH) Small molecule drug developed by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA). It is currently FDA-approved for Thromboprophylaxis in surgical patients, Thromboprophylaxis in medical patients at risk of venous thromboembolism, Treatment of deep vein thrombosis. Also known as: nadroparin, Fraxiparin.
Low-dose nadroparin is a low-molecular-weight heparin that inhibits blood coagulation by enhancing the activity of antithrombin III against factor Xa and thrombin.
Low-dose nadroparin is used to prevent Venous Thromboembolism (VTE) after bariatric surgery. It works by activating Antithrombin-III, a protein that helps regulate blood clotting.
At a glance
| Generic name | Low dose nadroparin |
|---|---|
| Also known as | nadroparin, Fraxiparin |
| Sponsor | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) |
| Drug class | Low-molecular-weight heparin (LMWH) |
| Target | Factor Xa, Thrombin (Factor IIa) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Nadroparin is derived from unfractionated heparin through chemical depolymerization, resulting in a low-molecular-weight heparin (LMWH) with a molecular weight of 4,300 Da. It potentiates antithrombin III-mediated inhibition of coagulation factors, particularly factor Xa (anti-Xa activity) and to a lesser extent thrombin (factor IIa). The low-dose formulation is used for thromboprophylaxis in clinical settings where prevention of venous thromboembolism is indicated.
Approved indications
- Thromboprophylaxis in surgical patients
- Thromboprophylaxis in medical patients at risk of venous thromboembolism
- Treatment of deep vein thrombosis
- Treatment of pulmonary embolism
Common side effects
- Bleeding
- Heparin-induced thrombocytopenia (HIT)
- Injection site reactions
- Osteoporosis (with long-term use)
Key clinical trials
- Short-term Low-dose Low-molecular-weight Heparin to Prevent Postpartum Thrombosis (PHASE3)
- Prevention of Postpartum Venous Thromboembolism in Women at Intermediate Risk (PHASE4)
- Apixaban, Warfarin and Aspirin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy（ESAWAAPT） (PHASE4)
- Leiden Trial in Prevention of Post-Operative ThromboEmbolic Events (NA)
- The PARTUM Trial: Postpartum Aspirin to Reduce Thromboembolism Undue Morbidity (PHASE3)
- Improving Outcome in Subarachnoid Hemorrhage wIth Nadroparine (PHASE2)
- Management of Atrial Fibrillation in Patients With Cancer (MAFIC Study)
- Rivaroxaban and Vitamin K Antagonists for the Anticoagulation for the Implantation of Vena Cava Filters (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Low dose nadroparin CI brief — competitive landscape report
- Low dose nadroparin updates RSS · CI watch RSS
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) portfolio CI
Frequently asked questions about Low dose nadroparin
What is Low dose nadroparin?
How does Low dose nadroparin work?
What is Low dose nadroparin used for?
Who makes Low dose nadroparin?
Is Low dose nadroparin also known as anything else?
What drug class is Low dose nadroparin in?
What development phase is Low dose nadroparin in?
What are the side effects of Low dose nadroparin?
What does Low dose nadroparin target?
Related
- Drug class: All Low-molecular-weight heparin (LMWH) drugs
- Target: All drugs targeting Factor Xa, Thrombin (Factor IIa)
- Manufacturer: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Thromboprophylaxis in surgical patients
- Indication: Drugs for Thromboprophylaxis in medical patients at risk of venous thromboembolism
- Indication: Drugs for Treatment of deep vein thrombosis
- Also known as: nadroparin, Fraxiparin
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing